Immunic Inc (IMUX)

$16.90 +0.87 (5.43%)
Market Cap 218.71M
Revenue (ttm) 0.00
Net Income (ttm) -97.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 255,500
Avg Vol 179,542
Day's Range N/A - N/A
Shares Out 13.64M
Stochastic %K 92%
Beta 1.41
Analysts Strong Sell
Price Target $42.18

Company Profile

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restor...

Industry: Biotechnology
Sector: Healthcare
Phone: 332 255 9818
Website: imux.com
Address:
1200 Avenue of the Americas, Suite 200, New York, United States
Cattitude
Cattitude Aug. 19 at 11:43 AM
$IMUX one day soon we will wake up to $MRNA type gains, few more months 😎
0 · Reply
Jack8alot
Jack8alot Aug. 18 at 10:34 PM
$IMUX Definitely some snap crackle. I like the $.......00 Target before readout Whats your opinion $70. mine That would be starting point For the run to 900 in 27 21.53 next week
1 · Reply
ErnieWorthing84
ErnieWorthing84 Aug. 18 at 8:33 PM
$IMUX neat
1 · Reply
JimmyOcarri
JimmyOcarri Aug. 17 at 9:22 PM
$RTB $IMUX $BWAY $LVLU q
0 · Reply
JimmyOcarri
JimmyOcarri Aug. 17 at 7:33 PM
$NCEW $RTB $CCG $IMUX $BWAY gem---
0 · Reply
Mattjen
Mattjen Aug. 17 at 2:37 PM
$IMUX unusually quite.... 🤔
0 · Reply
takingstock73
takingstock73 Aug. 17 at 1:26 PM
$IMUX upgrades don't hurt
0 · Reply
Jw242
Jw242 Aug. 17 at 11:28 AM
$IMUX always get a kick out the name Wedbush who upgraded again
0 · Reply
Tlb123
Tlb123 Aug. 16 at 11:15 PM
$IMUX https://apple.news/AophjYQD5Q-qRufvYW3a1Qw
0 · Reply
tickertaco
tickertaco Aug. 15 at 4:51 PM
$IMUX Added my first video in over a year after finding this little beauty, let me know if it's a good evaluation. https://youtu.be/Fhx3moOutFk
0 · Reply
Latest News on IMUX
Immunic initiated with an Outperform at Wedbush

2026-08-17T11:20:15.000Z - 2 days ago

Immunic initiated with an Outperform at Wedbush

Immunic Earnings release: Q2 2026

Aug 11, 2026, 9:30 AM EDT - 8 days ago

Immunic Earnings release: Q2 2026

Immunic Quarterly report: Q2 2026

Aug 11, 2026, 9:30 AM EDT - 8 days ago

Immunic Quarterly report: Q2 2026

Immunic reports Q2 EPS (80c), consensus ($1.16)

2026-08-11T10:35:40.000Z - 8 days ago

Immunic reports Q2 EPS (80c), consensus ($1.16)

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 11, 2026, 6:30 AM EDT - 8 days ago

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Immunic Appoints Elena Ridloff to Board of Directors

Aug 10, 2026, 4:05 PM EDT - 8 days ago

Immunic Appoints Elena Ridloff to Board of Directors

Immunic Slides: Investor presentation

Jul 14, 2026, 9:00 AM EDT - 5 weeks ago

Immunic Slides: Investor presentation

Immunic to Participate in Investor Conferences in July

Jul 9, 2026, 6:30 AM EDT - 5 weeks ago

Immunic to Participate in Investor Conferences in July

Immunic to Participate in Investor, Industry and Scientific Conferences in June

Jun 10, 2026, 6:30 AM EDT - 2 months ago

Immunic to Participate in Investor, Industry and Scientific Conferences in June

Immunic Slides: Corporate presentation

Jun 1, 2026, 7:00 AM EDT - 2 months ago

Immunic Slides: Corporate presentation

Immunic Proxy statement: Proxy filing

May 29, 2026, 8:00 AM EDT - 2 months ago

Immunic Proxy statement: Proxy filing

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

May 28, 2026, 6:30 AM EDT - 2 months ago

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

Immunic CEO Daniel Vitt to step down, Erik Lundgren to succeed

2026-05-27T10:45:55.000Z - 3 months ago

Immunic CEO Daniel Vitt to step down, Erik Lundgren to succeed

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

May 27, 2026, 6:30 AM EDT - 3 months ago

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

B. Riley cuts Immunic target, sees ‘compelling entry point’

2026-05-22T13:43:24.000Z - 3 months ago

B. Riley cuts Immunic target, sees ‘compelling entry point’

Immunic appoints Michael Bonney as chair

2026-05-19T10:35:10.000Z - 3 months ago

Immunic appoints Michael Bonney as chair

BIIB

Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors

May 19, 2026, 6:30 AM EDT - 3 months ago

Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors

Immunic price target lowered to $19 from $26 at Roth Capital

2026-05-14T14:51:40.000Z - 3 months ago

Immunic price target lowered to $19 from $26 at Roth Capital

Immunic reports Q1 EPS ($1.08), consensus (96c)

2026-05-13T11:25:48.000Z - 3 months ago

Immunic reports Q1 EPS ($1.08), consensus (96c)

Immunic Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 3 months ago

Immunic Quarterly report: Q1 2026

Immunic Earnings release: Q1 2026

May 13, 2026, 7:00 AM EDT - 3 months ago

Immunic Earnings release: Q1 2026

Immunic Slides: Investor presentation

May 13, 2026, 7:00 AM EDT - 3 months ago

Immunic Slides: Investor presentation

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026, 6:30 AM EDT - 3 months ago

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Immunic initiated with an Outperform at LifeSci Capital

2026-05-04T11:36:42.000Z - 3 months ago

Immunic initiated with an Outperform at LifeSci Capital

Immunic Registration statement: Registration filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Immunic Registration statement: Registration filing

Immunic to Participate in Investor and Medical Conferences in May

Apr 30, 2026, 6:30 AM EDT - 3 months ago

Immunic to Participate in Investor and Medical Conferences in May

Immunic price target adjusted to $22 from $5 at H.C. Wainwright

2026-04-30T10:14:29.000Z - 3 months ago

Immunic price target adjusted to $22 from $5 at H.C. Wainwright

Immunic CMO Andreas Muehler to depart, Michael Panzara to succeed

2026-04-28T11:19:28.000Z - 4 months ago

Immunic CMO Andreas Muehler to depart, Michael Panzara to succeed

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.

Apr 28, 2026, 6:30 AM EDT - 4 months ago

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.

Immunic trading halted, news pending

2026-04-24T23:52:54.000Z - 4 months ago

Immunic trading halted, news pending

Immunic announces 1-for-10 reverse stock split

2026-04-23T12:08:47.000Z - 4 months ago

Immunic announces 1-for-10 reverse stock split

Immunic, Inc. Announces 1-for-10 Reverse Stock Split

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Immunic, Inc. Announces 1-for-10 Reverse Stock Split

Immunic initiated with a Buy at Stifel

2026-04-16T20:20:56.000Z - 4 months ago

Immunic initiated with a Buy at Stifel

Immunic downgraded to Hold from Buy at D. Boral Capital

2026-04-15T11:24:13.000Z - 4 months ago

Immunic downgraded to Hold from Buy at D. Boral Capital

Immunic to Participate in Scientific and Medical Conferences in April

Apr 9, 2026, 6:30 AM EDT - 4 months ago

Immunic to Participate in Scientific and Medical Conferences in April

Immunic files to sell 458.15M shares of common stock for holders

2026-04-02T20:35:15.000Z - 4 months ago

Immunic files to sell 458.15M shares of common stock for holders

Immunic Registration statement: Registration filing

Apr 2, 2026, 8:00 AM EDT - 4 months ago

Immunic Registration statement: Registration filing

Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 1, 2026, 6:30 AM EDT - 5 months ago

Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement

Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton

Mar 31, 2026, 6:30 AM EDT - 5 months ago

Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton

Immunic Transcript: Stifel 2026 Virtual CNS Forum

Mar 18, 2026, 12:00 PM EDT - 5 months ago

Immunic Transcript: Stifel 2026 Virtual CNS Forum

Immunic Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 10:40 AM EDT - 5 months ago

Immunic Transcript: Leerink Global Healthcare Conference 2026

Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium

Mar 10, 2026, 6:30 AM EDT - 5 months ago

Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium

Immunic to Participate in Investor Conferences in March

Mar 3, 2026, 6:30 AM EST - 6 months ago

Immunic to Participate in Investor Conferences in March

Immunic Proxy statement: Proxy Filing

Mar 2, 2026, 7:00 AM EST - 6 months ago

Immunic Proxy statement: Proxy Filing

Immunic Earnings release: Q4 2025

Feb 26, 2026, 7:00 AM EST - 6 months ago

Immunic Earnings release: Q4 2025

Immunic Annual report: Q4 2025

Feb 26, 2026, 7:00 AM EST - 6 months ago

Immunic Annual report: Q4 2025

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update

Feb 26, 2026, 6:30 AM EST - 6 months ago

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update

Immunic Proxy statement: Proxy Filing

Feb 20, 2026, 7:00 AM EST - 6 months ago

Immunic Proxy statement: Proxy Filing

Immunic Announces Closing of Oversubscribed Private Placement Financing

Feb 17, 2026, 4:05 PM EST - 6 months ago

Immunic Announces Closing of Oversubscribed Private Placement Financing

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

Feb 13, 2026, 6:30 AM EST - 6 months ago

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

Feb 4, 2026, 6:30 AM EST - 7 months ago

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

Immunic Highlights 2025 Accomplishments and Upcoming Milestones

Jan 7, 2026, 6:30 AM EST - 8 months ago

Immunic Highlights 2025 Accomplishments and Upcoming Milestones

Immunic Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 4, 2025, 9:35 AM EST - 9 months ago

Immunic Transcript: Evercore ISI 8th Annual HealthCONx Conference

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

Nov 26, 2025, 6:30 AM EST - 9 months ago

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

Immunic Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 9 months ago

Immunic Earnings release: Q3 2025

Immunic Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 9 months ago

Immunic Quarterly report: Q3 2025

Immunic Slides: Company Presentation

Nov 13, 2025, 7:00 AM EST - 9 months ago

Immunic Slides: Company Presentation

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 6:30 AM EST - 9 months ago

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Immunic to Participate in Industry and Investor Conferences in November

Oct 29, 2025, 6:30 AM EDT - 10 months ago

Immunic to Participate in Industry and Investor Conferences in November

Immunic to Participate in Scientific and Investor Conferences in October

Oct 1, 2025, 6:30 AM EDT - 11 months ago

Immunic to Participate in Scientific and Investor Conferences in October

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

Sep 25, 2025, 6:30 AM EDT - 11 months ago

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

Sep 9, 2025, 6:30 AM EDT - 1 year ago

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

Immunic Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 7:00 AM EDT - 1 year ago

Immunic Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Immunic Slides: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 7:00 AM EDT - 1 year ago

Immunic Slides: H.C. Wainwright 27th Annual Global Investment Conference

Immunic to Participate in Investor and Scientific Conferences in September

Sep 4, 2025, 6:30 AM EDT - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in September

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 6:30 AM EDT - 1 year ago

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Immunic Quarterly report: Q2 2025

Aug 7, 2025, 6:30 AM EDT - 1 year ago

Immunic Quarterly report: Q2 2025

Immunic Earnings release: Q2 2025

Aug 7, 2025, 6:30 AM EDT - 1 year ago

Immunic Earnings release: Q2 2025

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Jun 24, 2025, 6:30 AM EDT - 1 year ago

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Immunic Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 4:55 PM EDT - 1 year ago

Immunic Transcript: Jefferies Global Healthcare Conference 2025

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Jun 5, 2025, 6:30 AM EDT - 1 year ago

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Jun 3, 2025, 4:01 PM EDT - 1 year ago

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Immunic to Participate in Investor, Scientific and Industry Conferences in June

Jun 2, 2025, 6:30 AM EDT - 1 year ago

Immunic to Participate in Investor, Scientific and Industry Conferences in June

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

May 29, 2025, 7:05 AM EDT - 1 year ago

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

Immunic, Inc. Announces Proposed Public Offering

May 28, 2025, 4:02 PM EDT - 1 year ago

Immunic, Inc. Announces Proposed Public Offering

Immunic Quarterly report: Q1 2025

May 15, 2025, 12:00 AM EDT - 1 year ago

Immunic Quarterly report: Q1 2025

Immunic to Participate in Scientific and Industry Conferences in May

May 2, 2025, 6:30 AM EDT - 1 year ago

Immunic to Participate in Scientific and Industry Conferences in May

Immunic Transcript: Study Update

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Immunic Transcript: Study Update

Immunic Press release: Study Update

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Immunic Press release: Study Update

Immunic Slides: Study Update

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Immunic Slides: Study Update

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Apr 30, 2025, 7:30 AM EDT - 1 year ago

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Immunic Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Immunic Proxy statement: Proxy Filing

Immunic Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Immunic Proxy statement: Proxy Filing

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 10, 2025, 1:00 PM EDT - 1 year ago

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 9, 2025, 8:10 AM EDT - 1 year ago

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Apr 1, 2025, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Immunic Annual report: Q4 2024

Mar 30, 2025, 6:00 PM EDT - 1 year ago

Immunic Annual report: Q4 2024

Immunic Transcript: Leerink’s Global Healthcare Conference 2025

Mar 12, 2025, 10:00 AM EDT - 1 year ago

Immunic Transcript: Leerink’s Global Healthcare Conference 2025

Immunic to Participate in Scientific and Investor Conferences in March

Mar 3, 2025, 6:30 AM EST - 1 year ago

Immunic to Participate in Scientific and Investor Conferences in March

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Feb 26, 2025, 6:30 AM EST - 1 year ago

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Feb 20, 2025, 7:30 AM EST - 1 year ago

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Immunic Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 12, 2025, 1:20 PM EST - 1 year ago

Immunic Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Immunic to Participate in Investor and Scientific Conferences in February

Feb 4, 2025, 6:30 AM EST - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in February

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Jan 7, 2025, 6:30 AM EST - 1 year ago

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Immunic Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 5, 2024, 11:30 AM EST - 1 year ago

Immunic Transcript: Piper Sandler 36th Annual Healthcare Conference

Immunic, Inc. to Participate in Investor Conference in December

Nov 26, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. to Participate in Investor Conference in December

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Nov 13, 2024, 6:30 AM EST - 1 year ago

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Immunic Earnings Call Transcript: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Immunic Earnings Call Transcript: Q3 2024

Immunic Quarterly report: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Immunic Quarterly report: Q3 2024

Immunic Earnings release: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Immunic Earnings release: Q3 2024

Immunic Slides: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Immunic Slides: Q3 2024

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Oct 31, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Immunic to Participate in Industry, Scientific and Investor Conferences in November

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Industry, Scientific and Investor Conferences in November

Cattitude
Cattitude Aug. 19 at 11:43 AM
$IMUX one day soon we will wake up to $MRNA type gains, few more months 😎
0 · Reply
Jack8alot
Jack8alot Aug. 18 at 10:34 PM
$IMUX Definitely some snap crackle. I like the $.......00 Target before readout Whats your opinion $70. mine That would be starting point For the run to 900 in 27 21.53 next week
1 · Reply
ErnieWorthing84
ErnieWorthing84 Aug. 18 at 8:33 PM
$IMUX neat
1 · Reply
JimmyOcarri
JimmyOcarri Aug. 17 at 9:22 PM
$RTB $IMUX $BWAY $LVLU q
0 · Reply
JimmyOcarri
JimmyOcarri Aug. 17 at 7:33 PM
$NCEW $RTB $CCG $IMUX $BWAY gem---
0 · Reply
Mattjen
Mattjen Aug. 17 at 2:37 PM
$IMUX unusually quite.... 🤔
0 · Reply
takingstock73
takingstock73 Aug. 17 at 1:26 PM
$IMUX upgrades don't hurt
0 · Reply
Jw242
Jw242 Aug. 17 at 11:28 AM
$IMUX always get a kick out the name Wedbush who upgraded again
0 · Reply
Tlb123
Tlb123 Aug. 16 at 11:15 PM
$IMUX https://apple.news/AophjYQD5Q-qRufvYW3a1Qw
0 · Reply
tickertaco
tickertaco Aug. 15 at 4:51 PM
$IMUX Added my first video in over a year after finding this little beauty, let me know if it's a good evaluation. https://youtu.be/Fhx3moOutFk
0 · Reply
radonco
radonco Aug. 13 at 10:30 PM
$IMUX 7 year chart looking good 🤑
1 · Reply
Om05
Om05 Aug. 13 at 9:39 PM
$IMUX 😊✌️
0 · Reply
Jw242
Jw242 Aug. 13 at 4:07 PM
$IMUX vittardiolungren’d 😂
0 · Reply
Starflash
Starflash Aug. 13 at 2:47 PM
$IMUX My forecast is: Until December we go up to 18. 24 hours before the results of P3 we go to 21. Negative results will lead to a SP of 5. Positive results: Up to 50. After that a light drawback to 42. And after that everything can happen.
0 · Reply
Mvvh1987
Mvvh1987 Aug. 13 at 1:25 PM
$IMUX https://youtu.be/FvQJk-sfcMA?si=hhyJlsDiPMSv6CIM
0 · Reply
AitorMenta
AitorMenta Aug. 12 at 7:21 PM
$IMUX movement without much volume… We are handled. IMO, end of year are going to be crazy, we will see the direction…
0 · Reply
stillers2000
stillers2000 Aug. 12 at 6:36 PM
$IMUX checking in on this one. First purchased shares in the 50 and 60 cent range. I've sold and bought back in over time becuase I get distracted by other opportunities. Started buying back in about a month ago and looking to hold through Phase 3 trials at this point. Everything seems to be tracking nicely! Glad to see the same names still chatting on this board, too! $100 or $0 by end of year, folks
1 · Reply
Jw242
Jw242 Aug. 12 at 2:25 PM
$IMUX does Guggenheim not know about all the warrants Vitt handed out?
1 · Reply
rizmanasjr
rizmanasjr Aug. 12 at 12:02 PM
$IMUX
0 · Reply
takingstock73
takingstock73 Aug. 12 at 11:43 AM
$IMUX Guggenheim reiterated $70 strong buy , let's go
0 · Reply
ErnieWorthing84
ErnieWorthing84 Aug. 11 at 11:45 PM
$IMUX The Summer Vitt Turned Pretty
0 · Reply
takingstock73
takingstock73 Aug. 11 at 8:16 PM
$IMUX nice close
0 · Reply